Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2409923 | Vaccine | 2005 | 5 Pages |
Abstract
Finnish and Israeli infants received an 11-valent mixed carrier pneumococcal conjugate vaccine (11PCV) with or without aluminum adjuvant at the age of 2, 4, 6, and 12 months. We measured opsonophagocytic activity (OPA) of antibodies to pneumococcal strains of serotypes 4, 6B, 14, 19F, and 23F. At 7 months, OPA was clearly detected for all the serotypes. At 13 months, OPAs increased further and the proportion of individuals with a positive OPA ranged between 81 and 100%. The adjuvant improved functional activity of antibodies to serotype 6B pneumococci. In conclusion, immunization of infants with the 11PCV induced functionally active antibodies.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Tomi K Wuorimaa, Ron Dagan, Fabrice Bailleux, Raili Haikala, Nina Ekström, Juhani Eskola, Mansour Yaich, Helena Käyhty,